155 related articles for article (PubMed ID: 27177207)
21. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
22. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study.
Sánchez-Lander J; Cortiñas P; Loureiro CL; Pujol FH; Medina F; Capote-Negrín L; Bianchi G; García-Barriola V; Ruiz-Benni A; Avilán-Rovira J; Acosta H
Cancer Epidemiol; 2012 Oct; 36(5):e284-7. PubMed ID: 22608058
[TBL] [Abstract][Full Text] [Related]
24. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
Kjær SK; Frederiksen K; Munk C; Iftner T
J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
[TBL] [Abstract][Full Text] [Related]
25. Long-term cumulative incidence of cervical intraepithelial neoplasia grade 3 or worse after abnormal cytology: impact of HIV infection.
Massad LS; Pierce CB; Minkoff H; Watts DH; Darragh TM; Sanchez-Keeland L; Wright RL; Colie C; D'Souza G
Int J Cancer; 2014 Apr; 134(8):1854-61. PubMed ID: 24170366
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
27. Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: A nested case-control study in the Swiss HIV cohort study.
Clifford GM; Franceschi S; Keiser O; Schöni-Affolter F; Lise M; Dehler S; Levi F; Mousavi M; Bouchardy C; Wolfensberger A; Darling KE; Staehelin C; Bertisch B; Kuenzli E; Bernasconi E; Pawlita M; Egger M;
Int J Cancer; 2016 Apr; 138(7):1732-40. PubMed ID: 26537763
[TBL] [Abstract][Full Text] [Related]
28. A population-based study on the risk of cervical cancer and cervical intraepithelial neoplasia among grand multiparous women in Finland.
Hinkula M; Pukkala E; Kyyrönen P; Laukkanen P; Koskela P; Paavonen J; Lehtinen M; Kauppila A
Br J Cancer; 2004 Mar; 90(5):1025-9. PubMed ID: 14997202
[TBL] [Abstract][Full Text] [Related]
29. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
30. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women.
Massad LS; Xie X; Burk RD; D'Souza G; Darragh TM; Minkoff H; Colie C; Burian P; Palefsky J; Atrio J; Strickler HD
Am J Obstet Gynecol; 2016 Mar; 214(3):354.e1-6. PubMed ID: 26433170
[TBL] [Abstract][Full Text] [Related]
31. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
[TBL] [Abstract][Full Text] [Related]
32. Cervical intraepithelial neoplasia grade 2 or worse in human immunodeficiency virus-infected women with mildly abnormal cervical cytology.
Boardman LA; Cotter K; Raker C; Cu-Uvin S
Obstet Gynecol; 2008 Aug; 112(2 Pt 1):238-43. PubMed ID: 18669717
[TBL] [Abstract][Full Text] [Related]
33. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
[TBL] [Abstract][Full Text] [Related]
34. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
35. Impact of the human papillomavirus status on the development of high-grade cervical intraepithelial neoplasia in women negative for intraepithelial lesions or malignancy at the baseline: A 9-year Swedish nested case-control follow-up study.
Fröberg M; Östensson E; Belkić K; Oštrbenk A; Poljak M; Mints M; Arbyn M; Andersson S
Cancer; 2019 Jan; 125(2):239-248. PubMed ID: 30536370
[TBL] [Abstract][Full Text] [Related]
36. Persistence and clearance of high-risk human papillomavirus and cervical dysplasia at 1 year in women living with human immunodeficiency virus: a prospective cohort study.
Luckett R; Painter H; Hacker MR; Simon B; Seiphetlheng A; Erlinger A; Eakin C; Moyo S; Kyokunda LT; Esselen K; Feldman S; Morroni C; Ramogola-Masire D
BJOG; 2021 Nov; 128(12):1986-1996. PubMed ID: 34008294
[TBL] [Abstract][Full Text] [Related]
37. High-grade CIN on cervical biopsy and predictors of the subsequent cone histology results in women undergoing immediate conization.
Giannella L; Mfuta K; Gardini G; Rubino T; Fodero C; Prandi S
Eur J Obstet Gynecol Reprod Biol; 2015 Mar; 186():68-74. PubMed ID: 25656975
[TBL] [Abstract][Full Text] [Related]
38. Population fraction of cervical neoplasia attributable to high-risk human papillomaviruses.
Laukkanen P; Läärä E; Koskela P; Pukkala E; Virkkunen H; Lehtinen M
Future Oncol; 2010 May; 6(5):709-16. PubMed ID: 20465386
[TBL] [Abstract][Full Text] [Related]
39. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
40. A population-based study of age-related associations between vaginal pH and the development of cervical intraepithelial neoplasia.
Teng P; Hao M
Cancer Med; 2020 Mar; 9(5):1890-1902. PubMed ID: 31943830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
